Raffaele Baffa

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/12172797/publications.pdf

Version: 2024-02-01

40 papers	4,875 citations	201575 27 h-index	315616 38 g-index
40 all docs	40 docs citations	40 times ranked	7675 citing authors

#	Article	IF	Citations
1	The FHIT Gene, Spanning the Chromosome 3p14.2 Fragile Site and Renal Carcinomaâ€“Associated t(3;8) Breakpoint, Is Abnormal in Digestive Tract Cancers. Cell, 1996, 84, 587-597.	13.5	950
2	Micro-RNA profiling in kidney and bladder cancers. Urologic Oncology: Seminars and Original Investigations, 2007, 25, 387-392.	0.8	566
3	The FHIT Gene at 3p14.2 Is Abnormal in Lung Cancer. Cell, 1996, 85, 17-26.	13.5	529
4	MicroRNA expression profiling of human metastatic cancers identifies cancer gene targets. Journal of Pathology, 2009, 219, 214-221.	2.1	449
5	Reprogramming of miRNA networks in cancer and leukemia. Genome Research, 2010, 20, 589-599.	2.4	331
6	Gastric epithelial dysplasia in the natural history of gastric cancer: A multicenter prospective follow-up study. Gastroenterology, 1994, 107, 1288-1296.	0.6	240
7	Fragile genes as biomarkers: epigenetic control of WWOX and FHIT in lung, breast and bladder cancer. Oncogene, 2005, 24, 1625-1633.	2.6	164
8	Proepithelin Promotes Migration and Invasion of 5637 Bladder Cancer Cells through the Activation of ERK1/2 and the Formation of a Paxillin/FAK/ERK Complex. Cancer Research, 2006, 66, 7103-7110.	0.4	136
9	An Antimetastatic Role for Decorin in Breast Cancer. American Journal of Pathology, 2008, 173, 844-855.	1.9	136
10	A Novel Interaction between Perlecan Protein Core and Progranulin. Journal of Biological Chemistry, 2003, 278, 38113-38116.	1.6	119
11	Trichoplein/mitostatin regulates endoplasmic reticulumâ€“mitochondria juxtaposition. EMBO Reports, 2010, 11, 854-860.	2.0	114
12	MicroRNA expression profiling of male breast cancer. Breast Cancer Research, 2009, 11, R58.	2.2	103
13	MicroRNA expression profiling in human Barrett's carcinogenesis. International Journal of Cancer, 2011, 129, 1661-1670.	2.3	100
14	The Insulin-Like Growth Factor Receptor I Promotes Motility and Invasion of Bladder Cancer Cells through Akt- and Mitogen-Activated Protein Kinase-Dependent Activation of Paxillin. American Journal of Pathology, 2010, 176, 2997-3006.	1.9	91
15	Decorin Induces Mitophagy in Breast Carcinoma Cells via Peroxisome Proliferator-activated Receptor Î³ Coactivator-1Î± (PGC-1Î±) and Mitostatin. Journal of Biological Chemistry, 2014, 289, 4952-4968.	1.6	74
16	Fez1/Lzts1 Absence Impairs Cdk1/Cdc25C Interaction during Mitosis and Predisposes Mice to Cancer Development. Cancer Cell, 2007, 11, 275-289.	7.7	67
17	Proepithelin Regulates Prostate Cancer Cell Biology by Promoting Cell Growth, Migration, and Anchorage-Independent Growth. American Journal of Pathology, 2009, 174, 1037-1047.	1.9	66
18	Helicobacter pylori in promotion of gastric carcinogenesis. Digestive Diseases and Sciences, 1996, 41, 950-955.	1.1	61

#	Article	IF	Citations
19	Potential Cancer Therapy With the Fragile Histidine Triad Gene. JAMA - Journal of the American Medical Association, 2001, 286, 2441.	3.8	57
20	Loss of FHIT Expression in Transitional Cell Carcinoma of the Urinary Bladder. American Journal of Pathology, 2000, 156, 419-424.	1.9	55
21	Regression of upper gastric cancer in mice by FHIT gene delivery. FASEB Journal, 2003, 17, 1768-1770.	0.2	53
22	Fhit expression in gastric adenocarcinoma. , 2000, 88, 24-34.		46
23	Proepithelin is an autocrine growth factor for bladder cancer. Carcinogenesis, 2009, 30, 861-868.	1.3	41
24	FEZ1/LZTS1 Is Down-Regulated in High-Grade Bladder Cancer, and Its Restoration Suppresses Tumorigenicity in Transitional Cell Carcinoma Cells. American Journal of Pathology, 2002, 160, 1345-1352.	1.9	38
25	Advanced precancerous lesions within the GI tract: The molecular background. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2013, 27, 159-169.	1.0	37
26	Pluripotent Stem Cell miRNAs and Metastasis in Invasive Breast Cancer. Journal of the National Cancer Institute, 2014, 106, .	3.0	37
27	Transcribed ultraconserved noncoding RNAs (T-UCR) are involved in Barrett's esophagus carcinogenesis. Oncotarget, 2014, 5, 7162-7171.	0.8	35
28	Collecting duct carcinoma of the kidney: an immunohistochemical study of 11 cases. BMC Urology, 2004, 4, 11.	0.6	27
29	Inactivation of the FHIT Gene Favors Bladder Cancer Development. Clinical Cancer Research, 2004, 10, 7607-7612.	3.2	26
30	Mitostatin Is Down-Regulated in Human Prostate Cancer and Suppresses the Invasive Phenotype of Prostate Cancer Cells. PLoS ONE, 2011, 6, e19771.	1.1	22
31	Chromosomal deletions in bladder cancer: shutting down pathways. Frontiers in Bioscience - Landmark, 2007, 12, 826.	3.0	18
32	Fez1/Lzts1 -deficient mice are more susceptible to N -butyl- N -(4-hydroxybutil) nitrosamine (BBN) carcinogenesis. Carcinogenesis, 2008, 29, 846-848.	1.3	16
33	Prevention of urinary bladder cancer in the FHIT knock-out mouse with Rofecoxib, a Cox-2 inhibitor. Urologic Oncology: Seminars and Original Investigations, 2010, 28, 189-194.	0.8	14
34	Cancer Prevention and Therapy in a Preclinical Mouse Model: Impact of FHIT Viruses. Current Gene Therapy, 2004, 4, 53-63.	0.9	13
35	MicroRNA Dysregulation in Esophageal Neoplasia: The Biological Rationale for Novel Therapeutic Options. Current Pharmaceutical Design, 2012, 19, 1236-1241.	0.9	12
36	MicroRNAs and targeted therapy: small molecules of unlimited potentials. Current Opinion in Genetics and Development, 2013, 23, 75-77.	1.5	11

#	Article	IF	Citations
37	Loss of Fhit expression is associated with poorer survival in gastric cancer but is not an independent prognostic marker. Journal of Cancer Research and Clinical Oncology, 2006, 132, 45-50.	1.2	10
38	Targeted therapies in the management of metastatic bladder cancer. Biologics: Targets and Therapy, 2007, 1, 393-406.	3.0	8
39	Fhit expression in gastric adenocarcinoma. Cancer, 2000, 88, 24-34.	2.0	3
40	Analyzing the FHIT Gene by RT-PCR, Western Blotting, and Immunohistochemistry. Methods in Molecular Medicine, 2001, 53, 81-93.	0.8	0